CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review - Top-Institutions - MDSpire

CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review

  • By

  • Sheng-Guang Li

  • Ruohan Yu

  • Lina Zhang

  • Jing Zhang

  • Yadan Zou

  • Ji Li

  • Ting Long

  • Yanfeng Zhang

  • Jing Pan

  • July 1, 2026

  • 0 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, Maryland

    Key Differentiators

    • Rheumatology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Rheumatology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Rheumatology

  • #4

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, Pennsylvania

    Key Differentiators

    • Rheumatology
    • Oncology

  • #5

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Rheumatology

Original Source(s)

CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review

  • by Sheng-Guang Li, Ruohan Yu, Lina Zhang, Jing Zhang, Yadan Zou, Ji Li, Ting Long, Yanfeng Zhang, Jing Pan

  • July 1, 2026

Related Content

Connective tissue diseases combined with chronic myelomonocytic leukemia and myelofibrosis: a case report and literature review

Case report: Successful non-surgical management of massive isolated tricuspid Libman-Sacks endocarditis in a pregnant patient with SLE and secondary APS

How Epstein Barr virus shapes lupus autoimmunity: mechanistic insights and therapeutic perspectives